Antimicrobial activity of nanoconjugated glycopeptide antibiotics and their effect on Staphylococcus aureus biofilm by Berini, Francesca et al.
Frontiers in Microbiology | www.frontiersin.org 1 December 2021 | Volume 12 | Article 657431
ORIGINAL RESEARCH




State University of Londrina, Brazil
Reviewed by: 
Tao Jin, 









This article was submitted to 
Antimicrobials, Resistance and 
Chemotherapy, 
a section of the journal 
Frontiers in Microbiology
Received: 22 January 2021
Accepted: 09 November 2021
Published: 02 December 2021
Citation:
Berini F, Orlandi VT, Gamberoni F, 
Martegani E, Armenia I, Gornati R, 
Bernardini G and Marinelli F (2021) 
Antimicrobial Activity of 
Nanoconjugated Glycopeptide 




Antimicrobial Activity of 
Nanoconjugated Glycopeptide 
Antibiotics and Their Effect on 
Staphylococcus aureus Biofilm
Francesca Berini 1, Viviana Teresa Orlandi 1, Federica Gamberoni 1, Eleonora Martegani 1, 
Ilaria Armenia 2, Rosalba Gornati 1, Giovanni Bernardini 1 and Flavia Marinelli 1*
1 Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy, 2 Instituto de Nanociencia y Materiales 
de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza, Spain
In the era of antimicrobial resistance, the use of nanoconjugated antibiotics is regarded 
as a promising approach for preventing and fighting infections caused by resistant bacteria, 
including those exacerbated by the formation of difficult-to-treat bacterial biofilms. Thanks 
to their biocompatibility and magnetic properties, iron oxide nanoparticles (IONPs) are 
particularly attractive as antibiotic carriers for the targeting therapy. IONPs can direct 
conjugated antibiotics to infection sites by the use of an external magnet, facilitating tissue 
penetration and disturbing biofilm formation. As a consequence of antibiotic localization, 
a decrease in its administration dosage might be possible, reducing the side effects to 
non-targeted organs and the risk of antibiotic resistance spread in the commensal 
microbiota. Here, we  prepared nanoformulations of the ‘last-resort’ glycopeptides 
teicoplanin and vancomycin by conjugating them to IONPs via surface functionalization 
with (3-aminopropyl) triethoxysilane (APTES). These superparamagnetic NP-TEICO and 
NP-VANCO were chemically stable and NP-TEICO (better than NP-VANCO) conserved 
the typical spectrum of antimicrobial activity of glycopeptide antibiotics, being effective 
against a panel of staphylococci and enterococci, including clinical isolates and resistant 
strains. By a combination of different methodological approaches, we proved that 
NP-TEICO and, although to a lesser extent, NP-VANCO were effective in reducing biofilm 
formation by three methicillin-sensitive or resistant Staphylococcus aureus strains. 
Moreover, when attracted and concentrated by the action of an external magnet, NP-TEICO 
exerted a localized inhibitory effect on S. aureus biofilm formation at low antibiotic 
concentration. Finally, we proved that the conjugation of glycopeptide antibiotics to IONPs 
reduced their intrinsic cytotoxicity toward a human cell line.
Keywords: magnetic nanoparticles, iron oxide nanoparticles, teicoplanin, vancomycin, antimicrobial resistance, 
biofilm
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INTRODUCTION
The spread of antibiotic-resistant bacteria, exacerbated by 
the inappropriate use and abuse of antibiotics, is considered 
one of the main causes of morbidity and mortality worldwide, 
resulting in an increasing economic burden for the health 
systems (Cassini et al., 2018). Currently, drug-resistant bacteria 
cause 700,000 deaths per year and, according to the World 
Health Organization (WHO), by 2050, this number will reach 
10 million deaths per year if no action is taken (Inter-agency 
Coordination Group on Antimicrobial Resistance, 2019). 
Nowadays, the COVID-19 pandemic has further complicated 
the era of antimicrobial resistance (AMR), since most of 
the patients with COVID-19 are treated for presumptive or 
confirmed secondary infections by broad spectrum 
antimicrobials (Nieuwlaat et  al., 2020). One of the most 
common and difficult-to-treat drug-resistant infection is due 
to Staphylococcus aureus, whose incidence in hospital-acquired 
infections is very high. Indeed, recent data indicate that, in 
the WHO member states, from 20 to 80% of S. aureus clinical 
isolates are resistant to methicillin. Unfortunately, some of 
these isolates are also resistant to other antibiotics, including 
the last-resort carbapenems, glycopeptides, and more recently 
daptomycin (Gao et al., 2020; Shariati et al., 2020). Additionally, 
methicillin susceptible S. aureus (MSSA) or methicillin-resistant 
(MRSA) strains produce biofilms, which play a crucial role 
in establishing and sustaining difficult-to-treat severe infections 
such as osteomyelitis, endocarditis, and chronic bound 
infections (Uruén et  al., 2020). Biofilms consist of organized 
layers of bacteria cells attached to a surface and embedded 
in an extracellular polymeric matrix, which is a complex 
and variable biochemical mixture of polysaccharides, proteins, 
glycopeptides, nucleic acids, and lipids. Cells, once embedded 
in the biofilm, are protected from the host immunological 
response and become up to 1,000 times less susceptible to 
antibiotics than their planktonic mobile counterparts (Arciola 
et  al., 2018; Fulaz et  al., 2020). Medical devices, such as 
intravenous and urinary catheters, vascular, heart valve and 
joint prostheses, pacemakers, and contact lenses, provide 
excellent surfaces for S. aureus biofilm formation contributing 
to the diffusion and persistence of resistant infections (Arciola 
et  al., 2018).
Despite the burden of AMR, the number of novel antibiotic 
classes actually introduced into the market since 2000 is 
worryingly low. This is due to a multiplicity of factors, including 
difficulties in isolating novel molecules able to counteract the 
emerging resistance mechanisms and to eradicate biofilms, and 
a series of regulatory and economical constrains that affect 
antibiotic marketplace and discourage investments by pharma 
companies (Renwick and Mossialos, 2018). An alternative to 
the de novo antibiotic discovery, which is a long and costly 
process, is the development of diverse antimicrobial treatments 
by exploring less conventional solutions (i.e., using 
bacteriophages, antibacterial antibodies and peptides, 
photodynamic therapy) and by repurposing existing drugs using 
innovative formulations and administration routes (i.e., 
combining antibiotics with adjuvants or AMR inhibitors, 
liposomes, and nanomaterial for encapsulation and targeting; 
Mulani et  al., 2019; Naskar and Kim, 2019).
Nanomaterials can be  used as active therapeutic agents 
per se, or as carriers for already known antimicrobial 
molecules, or both (Gupta et  al., 2019). Silver, copper, 
copper oxide, zinc oxide, titanium oxide, and chitosan 
nanoparticles (NPs) are examples of nanomaterials with 
proven anti-microbial characteristics due to variegate and 
often not yet-completely understood mechanisms of actions 
(Joshi et  al., 2020; Wang et  al., 2020). Metal oxide NPs, 
in particular, are considered promising in penetrating tissues 
and disturbing biofilm structures, due to their physicochemical 
characteristics as small size, large surface-area-to-volume 
ratio, crystalline structure with a number of edges and 
corners and reactive sites, and, importantly, their potential 
to establish electrostatic interactions between their positively 
charged metal ions with the negatively charged biofilm 
matrix and bacteria cell envelopes (Al-Shabib et  al., 2018; 
Joshi et  al., 2020; Shkodenko et  al., 2020). Iron oxide NPs 
(IONPs) are a special class of metal oxide NPs possessing 
superparamagnetic properties (Ajinkya et  al., 2020). IONPs 
are already in use for diagnostic imaging (magnetic resonance 
imaging, MRI), cancer treatments (magnetic hyperthermia, 
thermal ablation), scaling up bioseparation processes and 
biosensing-based applications (Ajinkya et  al., 2020), and 
they are promising for remotely controlled nanoactuation 
of enzyme activity (Armenia et  al., 2019). As antibiotic 
carriers, IONPs offer the potential of specifically directing 
the active principles to the site of infection and/or conveying 
them deep into the biofilms by simply using an external 
magnetic field (Arias et  al., 2018; Shkodenko et  al., 2020). 
As a consequence, the efficacy of the localized antimicrobial 
treatment might increase, thus allowing the administration 
of lower doses with a consequent minimization of the 
intrinsic toxicity of the antibiotic to non-targeted and healthy 
organs and of systemic side effects. Moreover, the exposure 
of commensal microbiota to sub-lethal doses of the antibiotic 
might be reduced, thus preventing the rise of AMR. Clinical 
applications of magnetic IONPs are also supported by their 
physical and chemical stability and superior biocompatibility 
in comparison to other metal oxide NPs (Arias et  al., 2018; 
Shkodenko et  al., 2020) as well as by their relative safety 
(Bonfanti et  al., 2020).
In this paper, we  explored IONPs as carriers for two 
drugs of last resort, the glycopeptide antibiotics (GPAs) 
vancomycin and teicoplanin, currently in clinical use for 
treating severe infections caused by Gram-positive pathogens, 
including endocarditis, meningitis, and complicated skin, 
bloodstream, bone, and joint infections. Indeed, these GPAs, 
despite being relatively old antibiotics (with vancomycin 
approved by the Food and Drug Administration in the 1950s, 
and teicoplanin introduced in the European market in the 
1980s), still play a key role in mainstream therapy against 
MRSA and other clinically relevant Gram-positive pathogens 
(Butler et  al., 2014; Marcone et  al., 2018). Vancomycin and 
teicoplanin are natural products, synthesized by actinomycetes 
and formed by a nonribosomal heptapeptide scaffold, 
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decorated with sugar moieties, chlorine atoms, methyl groups, 
and, in the case of teicoplanin, a lipid chain (Yushchuk 
et  al., 2020a). They exert their antibacterial activity by 
inhibiting cell wall synthesis, through binding to the d-alanyl-
d-alanine terminus of the peptidoglycan precursor, thus 
leading to cell death (Binda et  al., 2014). Dose-dependent 
nephrotoxicity (more severe in the case of vancomycin) and 
poor penetration in biofilms and into certain body tissues 
are nowadays recognized as weak points in GPA therapeutic 
use (Van Bambeke, 2006; Gao et  al., 2020). Moreover, the 
spread of GPA-resistance, first among enterococci and then 
in staphylococci, has led WHO to include GPAs among the 
“watch group” of the Essential Medicine List, i.e., among 
those antimicrobials that should be  prescribed only for 
specific indications and subjected to stewardship programs 
and monitoring to avoid diffusion of resistant isolates (Sharland 
et  al., 2018). All these factors encourage searching and 
developing alternative formulations that might improve GPA 
delivery and efficacy, while keeping toxicity and resistance 
under control.
In the course of the past 10 years, different authors have 
investigated the possibility to incorporate vancomycin into 
several nanomaterials such as liposomes, chitosan scaffolds, 
or gold nanostars (Uhl et  al., 2017; Gonzalez Gomez et  al., 
2019; Karakeçili et  al., 2019; Wang et  al., 2019). Indeed, to 
the best of our knowledge, only two papers have explored 
the potential of vancomycin conjugation to IONPs, the first 
one for developing an affinity capture system for Gram-
positive and Gram-negative bacteria in biological samples 
(Kell et  al., 2008) and the more recent one for enhancing 
vancomycin sporicidal efficacy against Clostridium difficile 
(Chen et al., 2019). Less investigated has been the generation 
of nanosystems based on teicoplanin. The antimicrobial 
potential of nanocarried teicoplanin was reported only by 
Peng et al. (2010), who treated osteomyelitis with teicoplanin-
encapsulated biodegradable thermosensitive hydrogel; by 
Gonzalez Gomez et  al. (2019), who tested liposome-
encapsulated teicoplanin towards S. aureus; and by Ucak 
et  al. (2020), who reported teicoplanin delivery in poly 
lactic-co-glycolic acid NPs functionalized with S. aureus 
specific aptamers. In 2018, our group succeeded for the 
first time in conjugating teicoplanin to magnetic IONPs, 
after their functionalization with (3-aminopropyl) 
triethoxysilane (APTES; Armenia et al., 2018). In the present 
paper, we  have investigated the synthesis and the efficacy 
of IONPs carrying vancomycin and teicoplanin, as an 
innovative system for GPA formulation and use. We  have 
paid particular attention to the effect of the two 




Acetonitrile (CH3CN), ammonium formate (HCOONH4), 
ammonium hydroxide (NH4OH), (3-aminopropyl) triethoxysilane 
(APTES), bis(sulfosuccinimidyl) suberate (BS3), boric acid (H3BO3), 
crystal violet (C25N3H30Cl), 2′,7′-dichlorodihydrofluorescein (DCFH-
DA), 4,4-difluoro-1,3,5,7-tetramethyl-8(2′methoxyphenyl)-4-bora-
3a,4a-diaza-s-indacene, ethanol (C2H6O), ferric nitrate (Fe(NO3)3 × 9 
H2O), fetal bovine serum (FBS), formaldehyde (CH2O), glutamine 
(C5H10N2O3), glutaraldehyde (C5H8O2), hydrochloric acid (HCl), 
iron dichloride (FeCl2 × 4 H2O), iron trichloride (FeCl3 × 6 H2O), 
Luria Bertani broth (LB), Luria Bertani agar (LB agar), 
2-(N-morpholino) ethanesulfonic acid (MES), Müller Hinton agar 
(MHA), Müller Hinton broth 2 (MHB2), nitric acid (HNO3), 
osmium tetroxide (OsO4), phorbol 12-myristate 13-acetate (PMA), 
phosphate-buffered saline (PBS), potassium ferrocyanide 
(K4[Fe(CN)6] × 3H2O), RPMI-1640 medium, sodium chloride (NaCl), 
sodium hydroxide (NaOH), teicoplanin, tryptic soy broth (TSB), 
and vancomycin were purchased from Sigma-Aldrich, Milan, Italy. 
All chemical reagents were used without additional purification.
Microbial Strains and Culture Conditions
Escherichia coli ATCC 35218, Bacillus subtilis ATCC 6633, 
Staphylococcus aureus ATCC 6538P (MSSA), Staphylococcus 
aureus ATCC 25923 (MSSA), Staphylococcus aureus ATCC 
43300 (MRSA), Enterococcus faecalis ATCC 29212, and E. 
faecalis ATCC 51299 (VanB phenotype) were obtained from 
the American Type Culture Collection (ATCC). Enterococcus 
faecalis 9160188401-EF-34 (VanA phenotype) and Staphylococcus 
epidermidis strain 4 are clinical isolates, kindly provided by 
Laboratorio Microbiologia Clinica – Ospedale di Circolo, Varese, 
Italy. Staphylococcus haemolyticus 3902 is a teicoplanin-resistant 
clinical isolate (Beltrametti et  al., 2003), received from FIIRV 
(Fondazione Istituto Insubrico Ricerca per la Vita), Gerenzano 
Varese, Italy. For long-term preservation, bacterial cultures were 
stored at -80°C in 10% v/v glycerol.
E. coli and B. subtilis were routinely grown at 37°C with 
continuous shaking at 200 rpm (revolutions per minute) in LB 
broth. S. aureus, S. epidermidis, S. haemolyticus, and E. faecalis 
strains were propagated in the same conditions in MHB2. For 
exponential growth, overnight cultures were diluted in fresh 
medium at an optical density at 600 nm (OD600 nm) of 0.1 and 
incubated as above.
Synthesis of Nanoconjugated Antibiotics
Iron oxide (Fe2O3) NPs were synthetized using the co-precipitation 
method and functionalized with APTES, following the protocols 
described in Balzaretti et  al. (2017) and Armenia et  al. (2018). 
For conjugating vancomycin and teicoplanin, after having tried 
different combinations varying the GPAs and linker 
concentrations, the protocol used was the following. One 
milliliter of a 4 mg/ml suspension of NP-APTES in 10 mM 
borate buffer pH 8.2 was added with an amount of BS3 equal 
to 22.3 μg (for conjugation with teicoplanin) or 44.6 μg (in the 
case of vancomycin). The mixture was maintained under 
mechanical stirring for 1 h at room temperature. Subsequently, 
1 mg of teicoplanin or 2 mg of vancomycin was added to the 
NPs and the reaction allowed to proceed for 1 h at 40°C under 
mechanical agitation. The reaction was stopped by adding 500 μl 
of 10 mM Tris-HCl at pH 8.0. Nanoconjugated teicoplanin 
Berini et al. Nanoconjugated Teicoplanin and Vancomycin
Frontiers in Microbiology | www.frontiersin.org 4 December 2021 | Volume 12 | Article 657431
(NP-TEICO) and nanoconjugated vancomycin (NP-VANCO) 
were isolated using a magnet, resuspended in 30 mM MES 
buffer pH 6.0, and stored at 4°C. The amount of antibiotic 
bound to IONPs was estimated as follows:
 
conjugated GPA initial GPA added to the reaction mixture
free
=
- GPA measured in the supernatants after NP TEICO
 and NP VANCO
-
-  recovery by the magnet.
The GPA concentration in the supernatant was calculated 
by UV detection at 280 nm, using a UV-Vis JASCO V-460 
spectrophotometer (Jasco, Easton, United  States), and with the 
following linear regression equations: y = 0.0045x + 0.0373 
(R2 = 0.9908) for teicoplanin; y = 0.0038x + 0.01046 (R2 = 0.9999) 
for vancomycin.
NP Characterization
Shape, size, and size distribution of examined NPs were evaluated 
by transmission electron microscopy (TEM) using a JEOL 1010 
electron microscope (JEOL, Tokyo, Japan). Samples were 
appropriately diluted in MilliQ water and dispersed on carbon-
coated copper grids, then allowed to dry at room temperature. 
Hydrodynamic diameter and polydispersity index (PDI) were 
measured in MilliQ water at a concentration of 40 μg/ml of 
NPs. Electrophoretic mobility (ζ-potential) measurements were 
performed on samples (at 2 μg/ml final concentration) diluted 
in 1 mM KCl, using a 90 Plus Particle Size Analyzer (Brookhaven 
Instrument Corporation, Holtsville, United  States), operating at 
25°C. The effective conjugation of APTES, vancomycin, and 
teicoplanin to IONPs was followed by Fourier Transform Infrared 
Spectroscopy in Attenuated Total Reflectance (FTIR-ATR), too. 
For this analysis, 10 mg of the different NP preparations was 
dried in an oven at 50°C for 48 h and, subsequently, FTIR-ATR 
analysis was carried out using an infrared spectrophotometer 
(Cary 630 FTIR; Agilent Technologies, Santa Clara, United States).
Antimicrobial Susceptibility Test
Agar diffusion assay method was applied to evaluate the 
antimicrobial activity of NP-TEICO and NP-VANCO against 
B. subtilis ATCC 6633 and S. aureus ATCC 25923 (Armenia 
et  al., 2018). Briefly, bacterial cultures were grown in MHB2 
to an OD600 nm of 0.3–0.4 and then added at 10% v/v to MHA 
in Petri dishes. Ten microliter of IONPs, NP-TEICO, and 
NP-VANCO (at 4 mg/ml concentration, loaded with 615 μg/
ml teicoplanin for NP-TEICO or 840 μg/ml vancomycin for 
NP-VANCO) in 30 mM MES buffer pH 6.0, as well as 10 μl 
of teicoplanin and vancomycin in the same buffer (at a 
concentration equal to that loaded on the corresponding IONPs) 
was dropped onto the inoculated plates. Following incubation 
at 37°C for 24 h, diameters of zones of bacterial growth inhibition 
surrounding the droplets were measured.
Chemical Stability and Maintenance of the 
Antimicrobial Activity
NP-TEICO and NP-VANCO were stored at -20, 4, or 25°C 
up to 1 month. Every 7 days, samples were centrifuged at 
14,700 ×  g for 5 min: the concentration of free antibiotics in 
the supernatants was quantified by spectrophotometric assay 
at 280 nm and used to calculate the amounts of GPAs still 
bound to NPs. The antimicrobial activity of NP-TEICO and 
NP-VANCO was evaluated at the same time intervals by the 
antibiotic susceptibility test on S. aureus ATCC 25923.
Determination of Minimum Inhibitory 
Concentrations and Minimal Bactericidal 
Concentrations
Minimum inhibitory concentrations (MICs) of nonconjugated 
and nanoconjugated teicoplanin and vancomycin towards 
B. subtilis, S. aureus, S. epidermidis, S. haemolyticus, E. faecalis, 
and E. coli strains were determined following the guidelines 
of the Clinical and Laboratory Standards Institute (CLSI, 2018), 
with broth dilution method in MHB2. Hence, ca. 5 × 105 bacterial 
cells in exponential growth were inoculated into MHB2, 
supplemented with increasing concentrations of nonconjugated 
or nanoconjugated teicoplanin or vancomycin, dissolved in 
30 mM MES buffer pH 6.0, and incubated for 16–20 h at 37°C 
and 200 rpm. NP-TEICO and NP-VANCO concentrations to 
be added were calculated considering the amounts of teicoplanin 
or vancomycin loaded onto IONPs under the reaction conditions 
described above. MICs were expressed as the minimal 
concentrations of antibiotic at which no turbidity could 
be  detected. For the determination of minimal bactericidal 
concentrations (MBCs), 100 μl of bacterial cultures used for 
the MIC test were plated onto MHA, incubated at 37°C for 
24 h. MBCs were defined as the lowest concentrations of 
antibiotic at which no growth could be  seen. The tolerance 
level of each strain was calculated using the formula: 
Tolerance = MBC/MIC (May et  al., 1998).
Growth Kinetic Analysis and Viability 
Assay
Growth kinetics of B. subtilis ATCC 6633 and S. aureus ATCC 
25923 were assayed by growing the bacteria in 9 ml LB or 
MHB2, respectively, at 37°C and 200 rpm. One hour after the 
inoculum, bacterial cultures were added with 1 ml of NP-TEICO 
or NP-VANCO (at 4 mg/ml, corresponding to 615 μg/ml of 
loaded teicoplanin for NP-TEICO, or 840 μg/ml of conjugated 
vancomycin for NP-VANCO), or with nonconjugated teicoplanin 
or vancomycin (supplemented at the concentrations of the 
corresponding nanoconjugated antibiotics loaded onto IONPs). 
Growth was monitored by measuring the OD600 nm at regular 
time intervals, up to 5 h from the inoculum, when cultures 
reached the stationary phase of growth. At this point, 10 μl 
of undiluted or serially diluted bacterial cultures was plated 
on MHA. Plates were incubated at 37°C and after 24 h, viable 
counts (expressed as colony forming units per ml, CFU/ml) 
were estimated.
Fluorescence Microscopy Analysis
The LIVE/DEAD BacLight fluorescence assay (L7007, Molecular 
probes; ThermoFisher Scientific, Monza, Italy) was employed 
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to investigate the effect of nonconjugated and nanoconjugated 
GPAs on B. subtilis ATCC 6633 and S. aureus ATCC 25923 
cells, following the manufacturer’s instructions. After cultivation 
overnight at 37°C and 200 rpm, bacterial cultures were diluted 
at OD600 nm = 0.1  in 9 ml LB or MHB2 and incubated as above 
with 1 ml of nanoconjugated antibiotics (at a concentration of 
4 mg/ml), or with an amount of nonconjugated teicoplanin or 
vancomycin equal to that loaded onto the corresponding IONPs 
(615 μg/ml for teicoplanin, 840 μg/ml for vancomycin). After 
5 h, each bacterial solution was centrifuged at 3,300  × g for 
15 min, followed by re-suspension of the pellets in sterile saline 
solution (0.9% w/v NaCl). Samples were incubated at room 
temperature for 1 h with mixing every 15 min, then washed 
twice with saline solution. Pellets were finally re-suspended 
in 1 ml of saline solution and 3 μl of dye mixture was added, 
then incubated in dark for 15 min. Fluorescence images were 
acquired with an optical microscope with appropriate filters 
(Axiophot; Carl Zeiss, Milan, Italy), by trapping 5 μl of stained 
bacteria between a slide and a cover lip. Total fluorescence 
intensity of bacteria was quantified with the free open-source 
software ImageJ (National Institute of Health, Unites States; 
Schneider et  al., 2012). Intensities were indicated as % relative 
to the saturation fluorescence within the field. Red and green 
fluorescence stains corresponded to live or dead bacteria, 
respectively (Arakha et  al., 2015).
Biofilm Assay
Overnight cultures of S. aureus ATCC 6538P, S. aureus ATCC 
25923, and S. aureus ATCC 43300 were diluted 1:100  in fresh 
TSB medium and 1 ml of the diluted culture was added to 
each well of a 24-well polystyrene plate. On the basis of the 
previous experience on nanoconjugated teicoplanin inhibiting 
biofilm formation in S. aureus ATCC 6538P (Armenia et  al., 
2018), nonconjugated or nanoconjugated antibiotics were 
administered at concentrations corresponding to at least 4-fold 
the antibiotic MICs. An equivalent amount of IONPs was 
used as control. Cells were incubated at 37°C for 24 h (for 
S. aureus ATCC 6538P and ATCC 43300) or for 48 h (S. 
aureus ATCC 25923) and the inhibition of biofilm formation 
was evaluated as previously described (Armenia et  al., 2018). 
Briefly, planktonic biomass was removed and collected, and 
wells were washed once with 1 ml of PBS. Adherent biomass 
was quantified by crystal violet (CV) staining as follows: 1 ml 
of 0.1% w/v CV was added to each well for approximately 
20 min to stain the biofilm, after which CV was removed, 
and each well was washed twice with 1 ml PBS. The remaining 
CV, indicating the amount of biofilm, was dissolved in acetic 
acid 33% v/v for 10 min and spectrophotometrically measured 
at 590 nm. In order to evaluate the effect of different treatments 
on cellular viability, the planktonic phase was axenically 
collected, adherent cells were recovered by carefully scraping 
them and suspended in 1 ml of PBS by mild pipetting. Viable 
counts – expressed as CFU per ml (CFU/ml) in cell suspensions 
and as CFU per well (CFU/well) in adherent biomass – were 
estimated using a plate count technique. A volume (10 μl) 
of undiluted or serially diluted samples was plated onto LB 
agar plates and incubated for 24 h at 37°C. Three replicates 
for each condition were analyzed within one experiment, and 
each experiment was repeated at least three times, using 
independent cultures.
Confocal Analyses of Biofilm
Overnight S. aureus ATCC 6538P cultures were diluted 
1:100  in TSB medium. A sample of 3 ml of diluted culture 
was added to a glass coverslip placed on the bottom of 
35 mm diameter Petri dishes. Nonconjugated or nanoconjugated 
teicoplanin were added at 4 μg/ml final concentration, and 
the corresponding concentration of IONPs was used as control. 
After 24 h of incubation at 37°C, the planktonic phase was 
removed and adherent cells were stained with fluorochrome 
4,4-difluoro-1,3,5,7-tetramethyl-8(2′methoxyphenyl)-4-bora-
3a,4a-diaza-s-indacene at 5 μM (Sunahara et  al., 2007). To 
allow the penetration of the dye in the deepest layers of 
the biofilm, plates were incubated at 37°C for 30 min, under 
agitation at 50 rpm. Then, the coverslips were gently washed 
with PBS and transferred on microscope glass slides for the 
image acquisition through a 63× objective lens (Confocal 
light microscopy; Leica Microsystems, Wetzlar, Germany). 
Simulated 3D images were generated using ImageJ (Schneider 
et  al., 2012).
Application of an External Magnet Field to 
Biofilms
An external magnetic field can direct antibiotics conjugated 
to magnetic NPs to a specific site, as a biofilm-colonized surface, 
increasing local drug concentration and possibly improving 
the efficacy of the antibacterial treatment. To evaluate this 
aspect, overnight S. aureus ATCC 6538P cultures were diluted 
1:100  in fresh TSB medium and 0.5 ml of the culture was 
distributed in 24-well polystyrene plate. Nonconjugated and 
nanoconjugated teicoplanin (1 μg/ml) and the corresponding 
concentration of IONPs were administered, and a cubic magnet 
(5 × 5 × 5 mm) was positioned under each well. After 24 h of 
bacterial growth at 37°C, planktonic cells were removed, and 
the adherent biomass was quantified by CV staining as 
previously described.
Cytotoxicity Test and Macrophage Uptake 
of NPs
In vitro cytotoxicity of NP-TEICO and NP-VANCO was estimated 
on the tumor cell line SKOV-3 from ovary adenocarcinoma, 
cultured as previously reported (Cappellini et al., 2015; Armenia 
et  al., 2018). Cell cytotoxicity was determined measuring ATP 
content with the RealTime-Glo™ MT Cell Viability Assay 
(Promega, Milan, Italy), according to the manufacturer’s 
instructions. Five hundred cells were plated in a 96-well plate 
with 200 μl of RPMI-1640 cell medium. After 24 h, cells were 
exposed to increasing concentrations of nanoconjugated or 
nonconjugated GPAs, or to an equivalent concentration of 
IONPs. A 2× solution of the substrate and NanoLuc® Enzyme 
was added, followed by cell incubation at 37°C in 5% CO2-
humidified atmosphere. Luminescence was read every 24 h 
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using the Infinite F200 plate reader (Tecan Group, Männedorf, 
Switzerland).
For the phagocytosis assay, the human promonocytic THP-1 
cell line (Scaldaferri et  al., 2018) was cultured in RPMI-1640 
medium added with 10% v/v FBS and 1% w/v glutamine, and 
maintained in a humidified incubator (37°C, 5% CO2). THP-1 
cells, at a concentration of 105 cells/ml, were differentiated into 
M0 macrophages by the addition of 5 ng/ml PMA for 48 h as 
reported by Scaldaferri et al. (2018). Differentiation was performed 
on glass coverslips (12 mm Ø) placed on the bottom of 12-well 
assay plates. Cells were then incubated for 24 h with 5 and 
50 μg/ml IONPs, NP-TEICO, and NP-VANCO and visualized 
by Prussian Blue staining for iron detection. Cells were fixed 
in ice-cold ethanol for 5 min, stained with an equal volume of 
2% v/v hydrochloric acid and 2% w/v potassium ferrocyanide 
trihydrate for 15 min. Samples were then washed with distilled 
water and dried by increasing concentrations of ethanol, then 
mounted in DePeX (Serva, Heidelberg, Germany). Observations 
were performed with a Zeiss Axiophot microscope under bright 
light illumination and photographs were acquired by a Zeiss 
AxioCam ERc5s camera (Carl Zeiss, Milan, Italy).
Statistics
All experiments were repeated at least three times. Mean and 
standard deviation (SD) were calculated using Microsoft Excel 
2003 (Microsoft Corporation, Redmond, United  States). Data 
were analyzed by a one-way ANOVA (Origin_7.0 SR0; Origin 
lab Corporation, Northampton, United States). Significant effects 
of treatments were estimated (p < 0.05, p < 0.01, and p < 0.0001).
RESULTS
Synthesis and Physical Characterization of 
Nanoconjugated GPAs
Iron oxide nanoparticles were synthetized by the co-precipitation 
method, using the protocol by Balzaretti et al. (2017) optimized 
by Armenia et  al. (2018). Conjugation of GPAs to NP-APTES 
was conducted by using the homobifunctional cross-linker BS3, 
which contains an amine-reactive N-hydroxysulfosuccinimide 
(NHS) ester at each end of an 8-carbon spacer arm. The NHS 
esters reacted with the amines present in the antibiotic molecules 
(one reactive amino group in teicoplanin and two in vancomycin), 
thus forming stable amidic bonds (Figure  1).
Conjugation of NPs with GPAs was followed by FTIR-ATR, 
as shown in Supplementary Figure S1. Spectra of IONPs 
showed the bands characteristic for the Fe-O bond; the 
functionalization with APTES and the conjugation with 
teicoplanin or vancomycin introduced specific changes in the 
corresponding IR spectra, indicating the formation of covalent 
bonds linking antibiotics to IONPs (Supplementary Figure S1). 
TEM micrographs (Supplementary Figures S2A,E) showed 
that IONPs had a spherical shape and an average diameter 
of 9.3 ± 2.6 nm, with good stability and no tendency to aggregation. 
Diameter was not influenced by the functionalization of IONPs 
with APTES (diameter of NP-APTES = 9.2 ± 3.1 nm; 
Supplementary Figures S2B,F) and was only slightly increased 
by conjugating GPAs (Supplementary Figures S2C,D,G,H). 
Both NP-TEICO and NP-VANCO presented spherical shapes, 
with an average diameter of 9.9 ± 3.2 nm and 10.3 ± 3.6 nm, 
respectively.
Dynamic light scattering (DLS) was employed to measure 
the hydrodynamic size of the different NPs 
(Supplementary Table S1). Diameter and average size distribution 
(PDI) of IONPs and NP-APTES were in line with previous 
results (Armenia et  al., 2018). IONPs presented a slight 
polydispersity, typical for NPs synthesized by co-precipitation 
method (Wu et al., 2015) and an average diameter of 14.5 ± 0.7 nm. 
The addition of the APTES coating to the NP core determined 
a rise in the hydrodynamic diameter (25.8 ± 0.7 nm), but the 
most evident increase was observed after conjugation of the 
two GPAs (380.0 ± 2.0 nm for NP-TEICO, 628.0 ± 1.5 nm for 
NP-VANCO). As previously observed (De Palma et  al., 2007; 
Gonçalves et al., 2017), NP sizes estimated by DLS are significantly 
different from those obtained by TEM observations. This 
phenomenon is generally associated to the formation of additional 
hydrate layers in aqueous solutions due to antibiotic shells 
around NPs, which are not enough electron dense to be detected 
at the electron microscope. Additionally, a partial aggregation 
of the conjugated NPs in the experimental conditions used 
for DLS analysis might contribute to such an increase in 
hydrodynamic sizes (Szpak et  al., 2013). Although teicoplanin 
and vancomycin are both glycosylated heptapeptides, the 
hydrodynamic size of NP-VANCO significantly exceeded the 
one of NP-TEICO; this could be  probably explained by the 
more hydrophobic nature of teicoplanin due to the lipid tail 
present in teicoplanin and absent in vancomycin (Treviño et al., 
2014; Marcone et  al., 2018).
The measurement of ζ-potential (Supplementary Table S1) 
confirmed the correct coating of IONPs: indeed, a more positive 
net charge was observed, as a consequence of the presence 
of the positive amino groups of APTES on the particle surface. 
The additional conjugation of the GPAs led to a further increase 
in ζ-potential, which guaranties the colloidal stability of the 
nano-GPA systems.
Different combinations of GPA and BS3 linker concentrations 
were then used to optimize the antibiotic binding to NP-APTES 
(data not shown). Under the best reaction conditions so far 
identified (for teicoplanin: 4 mg/ml of NP-APTES in 10 mM 
borate buffer pH 8.2, 22.3 μg/ml BS3, 1 mg/ml teicoplanin; for 
vancomycin: an equal amount of NP-APTES in the same buffer, 
44.6 μg/ml BS3, 2 mg/ml vancomycin), 155 ± 14 μg of teicoplanin 
and 210 ± 40 μg of vancomycin were loaded on average per 
mg of IONPs (data achieved after a dozen of different preparations 
for each GPA), corresponding to an average of 61.5 and 42% 
conjugation yield for teicoplanin and vancomycin, respectively. 
The chemical stability of the so-prepared NP-TEICO and 
NP-VANCO was tested at -20, 4, and 25°C. Measuring the 
release of teicoplanin and vancomycin by spectrophotometric 
analysis of the incubation buffer, ca. 25 and 30% of teicoplanin 
and vancomycin, respectively, were released after the first week 
of conservation. After that, the nanoconjugated antibiotic 
preparations remained considerably stable: after 4 weeks, 
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approximately 60% of teicoplanin and ca. 70% of vancomycin 
were still bound to IONPs.
Antimicrobial Activity of Nanoconjugated 
GPAs
Antibacterial activity of the two nanoformulations was tested 
by agar diffusion assay towards two Gram-positive bacteria 
(S. aureus ATCC 25923 and B. subtilis ATCC 6633) and one 
Gram-negative bacterium (E. coli ATCC 35218). As expected 
for GPAs, both NP-TEICO and NP-VANCO were able to inhibit 
the growth of Gram-positives (Supplementary Figure S3), 
while no inhibition was observed for E. coli (data not shown). 
Notably, no inhibition halos were formed by the equivalent 
concentration of IONPs (Supplementary Figure S3), confirming 
that the antimicrobial activity of NP-TEICO and NP-VANCO 
is due to the conjugated GPAs and not to the NPs themselves. 
After 4 weeks from their preparation, NP-TEICO and NP-VANCO 
maintained 70 and 55%, respectively, of their initial antimicrobial 
activity, consistently with the data on the chemical stability, 
reported above. Under the same conditions, water solutions 
of teicoplanin and vancomycin retained ca. 90% of their initial 
antimicrobial activity.
Table  1 reports the MICs and the MBCs of nonconjugated 
and nanoconjugated teicoplanin and vancomycin towards a 
collection of clinically relevant microorganisms, including S. 
aureus, S. epidermidis, S. haemolyticus, and E. faecalis strains. 
MICs of nonconjugated teicoplanin and vancomycin were 
comparable against B. subtilis, MSSA, MRSA, and S. epidermidis 
strains, which were all susceptible to both antibiotics [i.e., with 
MIC ≤2 μg/ml, as defined by the Clinical and Laboratory 
Standards Institute (CLSI, 2018)]. E. faecalis ATCC 29212 and 
VanB-type E. faecalis ATCC 51299 were susceptible to teicoplanin, 
being on the contrary intermediate-resistant (i.e., MIC between 
4 and 8 μg/ml) or resistant (i.e., MIC ≥16 μg/ml), respectively, 
to vancomycin. S. haemolyticus 3902 was resistant to teicoplanin 
and susceptible to vancomycin, as previously reported (Biavasco 
et  al., 2000). MICs and MBCs of NP-TEICO towards all these 
susceptible and resistant strains followed the same trends as 
those measured for the nonconjugated antibiotic, confirming 
that nanoconjugated teicoplanin conserved the same spectrum 
of action, with only a slight reduction in potency. Instead, 
the potency reduction after antibiotic conjugation was more 
evident in the case of NP-VANCO, when compared to the 
activity of the corresponding nonconjugated antibiotic. Indeed, 
some Gram-positives (i.e., B. subtilis, MSSA ATCC 6538P, 
MRSA, S. haemolyticus, and S. epidermidis), susceptible to free 
vancomycin, were intermediately resistant towards NP-VANCO. 
As expected, nanoconjugated and nonconjugated GPAs were 
inactive toward VanA-type E. faecalis 9160188401-EF-34 (Van 
Bambeke, 2006; Binda et  al., 2014) and the Gram-negative 
E. coli.
Effects of Nanoconjugated GPAs on the 
Bacterial Growth Kinetics and Cell Viability
The effect of the two nanoconjugated GPAs on the growth 
and viability of representative Gram-positive bacteria was 
further investigated. Equal concentrations of nonconjugated 
or nanoconjugated teicoplanin or vancomycin were added at 
the log phase during the growth kinetics of S. aureus ATCC 
25923 and B. subtilis ATCC 6633. Cultures without any addition 
or supplemented with an equivalent amount of IONPs were 
used as controls. In both the bacteria, the addition of 
nonconjugated and nanoconjugated GPAs prevented the 
bacterial population to enter into the exponential growth 
phase. The extent of the growth inhibition effect was comparable 
among teicoplanin, vancomycin, NP-TEICO, and NP-VANCO 
A B
FIGURE 1 | Schematization of the conjugation chemistry used to link teicoplanin and vancomycin onto iron oxide nanoparticles (IONPs; not in scale). Panel A: 
Surface modification steps with APTES functionalization (1) and subsequent BS3 linker binding (2). Panel B: 3D molecular structures of vancomycin (1, PDB entry 
1FVM) and teicoplanin (2, PDB entry 3VFK). Blue spheres indicate amine groups used for conjugating GPAs to BS3 moiety. In (B), GPA structures were rendered 
with 3D ProteinImager (Tomasello et al., 2020).
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(Figures  2A,C). Indeed, the addition of IONPs determined 
particularly for B. subtilis a slight reduction in the normal 
growth rate, probably due to a transient species-specific 
electrostatic interaction occurring between bacterial cells and 
IONPs, as previously reported by other authors (Ebrahiminezhad 
et  al., 2014; Arakha et  al., 2015; Dinali et  al., 2017; Armenia 
et  al., 2018; Shkodenko et  al., 2020). Consistently, CFU 
measurements at the end of the experiment clearly showed 
that exposing B. subtilis and S. aureus to nonconjugated or 
nanoconjugated antibiotics caused an almost complete clearance 
of bacterial populations, thus confirming the antibiotic activity 
of nanoconjugated GPAs against Gram-positives 
(Figures  2B,D). The effect of IONPs was also in this case 
slightly different between the two microorganisms: in the 
case of S. aureus ATCC 25923 no bactericidal effect of IONPs 
was observed, as cell survival percentage was equal to that 
of the untreated population (Figure  2D). A reduction in cell 
viability was, instead, observed after exposure of B. subtilis 
ATCC 6633 to IONPs (Figure  2B), although this difference 
was not statistically significant and not comparable to the 
clear bactericidal activity of nanoconjugated and 
nonconjugated GPAs.
The LIVE/DEAD BacLight fluorescence assay 
(Supplementary Figure S4) confirmed the bactericidal effect 
of nanoconjugated antibiotics on S. aureus and B. subtilis. In 
this assay, viable cells are stained green by the Syto9 fluorescence 
dye, whereas nonviable cells are stained red by propidium 
iodide fluorescence dye (Arakha et  al., 2015). Untreated cells 
of both S. aureus ATCC 25923 and B. subtilis ATCC 6633 
(Supplementary Figures S4A,B) were stained green by Syto9 
dye, indicating the presence of 85% viable cells for B. subtilis 
and 98% for S. aureus. Instead, cells turned red after exposure 
to both nonconjugated or nanoconjugated teicoplanin 
(Supplementary Figures S4C–F) and vancomycin 
(Supplementary Figures S4G–J), thus confirming the bactericidal 
effect of GPAs in both forms. Interestingly, when NP-TEICO 
or NP-VANCO was present, bacteria tended to aggregate on 
them (Supplementary Figures S4E,F,I,J), further favouring the 
clearance of bacterial populations.
Effect of Nanoconjugated GPAs on 
Staphylococcus aureus Biofilms
NP-TEICO, NP-VANCO and their nonconjugated GPAs were 
tested on S. aureus biofilms (Figure  3) using three different 
strains of S. aureus (Table  1) – i.e., two methicillin sensitive 
S. aureus strains (ATCC 25923 and ATCC 6538P) and one 
resistant strain (ATCC 43300) – known from the literature 
for producing biofilms at different extent (Rose and Poppens, 
2009; Artini et  al., 2012). The effect of IONPs per se was 
ruled out by preliminary experiments (Supplementary Table S2), 
in which different concentrations of IONPs were tested on 
planktonic and adherent subpopulations of the biofilms formed 
by the three S. aureus strains. None statistically significant 
inhibitory activity on biofilm production and cell viability by 
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S. aureus ATCC 25923 was the most sensitive strain 
among the three, to both teicoplanin and vancomycin 
(MIC = 0.25 μg/ml, Table  1). Nanoconjugated and 
nonconjugated antibiotics were tested at concentrations 
corresponding to four-fold the MIC, i.e., 1 μg/ml. As shown 
in Figure  3A, NP-TEICO inhibited biofilm formation at a 
similar extent to teicoplanin: a decrease of ~60% in adherent 
biomass was detected, compared to the untreated sample. 
Furthermore, both formulations of teicoplanin caused a 
significant decrease (~3 Log unit) in cell count of both 
adherent and planktonic cells (Figures  3A,B). Conversely, 
NP-VANCO was less active than vancomycin on both adherent 
and planktonic populations (Figures  3G,H). Additionally, 
NP-VANCO (Figures  3G,H) was also less effective than the 
corresponding preparation of NP-TEICO (Figures  3A,B).
S. aureus ATCC 6538P was a better biofilm former than 
S. aureus ATCC 25923: it formed in 24 h an adherent 
biomass two-fold more abundant if compared to the one 
produced by ATCC 25923 strain in 48 h of growth (CTRL 
bars in Figures 3C,D,I,J). As reported in Table 1, S. aureus 
ATCC 6538P was also less susceptible than S. aureus ATCC 
25923 to both teicoplanin and vancomycin (MIC = 1 μg/
ml, Table  1). Formulations of nonconjugated and 
nanoconjugated teicoplanin (Figures 3C,D) and vancomycin 
(Figures  3I,J) were thus administered at a concentration 
of 4 μg/ml, four-fold the MIC. In the case of NP-TEICO, 
A B
C D
FIGURE 2 | Population growth kinetics of B. subtilis ATCC 6633 (panel A) and S. aureus ATCC 25923 (panel C) exposed to 0.4 mg/ml of IONPs (green), NP-
VANCO (blue, corresponding to 84 μg/ml of conjugated vancomycin), NP-TEICO (orange, corresponding to 61.5 μg/ml of conjugated teicoplanin), or to 
nonconjugated teicoplanin (TEICO, violet) and vancomycin (VANCO, turquoise), supplemented at the concentrations of the corresponding nanoconjugated 
antibiotics loaded onto IONPs. Cultures without any addition (CTRL, red) were used as control. Black arrows indicate the addition (after 1 h) of IONPs, or 
nanoconjugated, or nonconjugated antibiotics to bacterial populations. In panels B and D, bacterial cell viability of B. subtilis ATCC 6633 and S. aureus ATCC 
25923, respectively, measured as CFU/ml after 5-h growth. Experiments were conducted in triplicate for each condition. Statistical analyses were performed by 
one-way ANOVA (**p < 0.01; ***p < 0.0001).
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its effect was similar to teicoplanin and caused a significant 
inhibition of biofilm formation: a ~95% decrease in adherent 
biomass and a ~3 Log unit reduction of sessile cell counting 
was observed (Figure  3C). A 5 Log unit decrease in 
planktonic cell concentration was observed under treatment 
with both nonconjugated and nanoconjugated teicoplanin 
(Figure  3D). In the case of NP-VANCO, the effect was 
similar to vancomycin on biofilm adherent biomass 
(Figure  3I), which was inhibited of almost 90% by both 
nonconjugated and nanoconjugated vancomycin. The two 
formulations differed in their activity vs. the planktonic 
cells: cell count of vancomycin-treated planktonic cells was 
significantly lower (~3 Log units) than in untreated samples, 
but NP-VANCO activity on planktonic cells was lowered 
in comparison to nonconjugated vancomycin (Figure  3J). 
Vancomycin per se (Figures  3I,J) was indeed less active 
than teicoplanin (Figures  3C,D) especially on planktonic 
cell population.
Finally, the methicillin-resistant S. aureus ATCC 43300 strain 
(MRSA) was found to form less biofilm than ATCC 6538P 
strain (CTRL bars in Figures  3E,F,K,L), but its biofilm was 
particularly tolerant to antibiotics. At 2 μg/ml teicoplanin 
concentration (four-fold the MIC of 0.5 μg/ml, Table  1), none 
significant inhibitory effect on biofilm formation was observed 
(data not shown) and it was necessary to administer 8 μg/ml 
of teicoplanin, a concentration 16-fold higher than the MIC, 
to get an inhibitory effect. At this concentration, teicoplanin 
inhibited biofilm formation causing a ~80% decrease in adherent 
biomass and ~3 Log unit decrease in its cell viability as compared 
to untreated cells. The inhibitory effect of NP-TEICO was 
slightly reduced in comparison with teicoplanin, causing a 







FIGURE 3 | Inhibition of biofilm formation in three S. aureus strains by nonconjugated and nanoconjugated teicoplanin or vancomycin. In all panels, ‘CTRL’ refers to 
the untreated control. Panels A and B: effect of nonconjugated or nanoconjugated teicoplanin at 1 μg/ml on biofilm formation by S. aureus ATCC 25923 grown for 
48 h. Panels C and D: effect of nonconjugated or nanoconjugated teicoplanin at 4 μg/ml on biofilm formation by S. aureus ATCC 6538P grown for 24 h. Panels E 
and F: effect of nonconjugated or nanoconjugated teicoplanin at 8 μg/ml on biofilm formation by S. aureus ATCC 43300 grown for 24 h. Panels G and H: effect of 
nanoconjugated and nonconjugated vancomycin at 1 μg/ml on biofilm formation by S. aureus ATCC 25923 grown for 48 h. Panels I and J: effect of nanoconjugated 
and nonconjugated vancomycin at 4 μg/ml on biofilm formation by S. aureus ATCC 6538P grown for 24 h. Panels K and L: effect of nanoconjugated and 
nonconjugated vancomycin at 16 μg/ml on biofilm formation by S. aureus ATCC 43300 grown for 24 h. Adherent biomass is estimated spectrophotometrically at 
590 nm after crystal violet staining (violet bars in A,C,E,G,I,K) and by bacterial cell counting of sessile cells expressed as CFU/well (grey bars in A,C,E,G,I,K). Cellular 
concentration (CFU/ml) of planktonic population was also evaluated (green bars in B,D,F,H,J,L). The values are the means of at least three independent 
experiments and the bars represent standard deviations. Statistical analyses were performed by one-way ANOVA (*p < 0.05; **p < 0.01; ***p < 0.0001).
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decrease in adherent cell viability (Figure  3E). Reductions of 
~4 and ~3 Log units were observed in suspended cell counts, 
following the treatment with teicoplanin and NP-TEICO, 
respectively (Figure  3F). Nonconjugated and nanoconjugated 
vancomycin were tested at an equivalent concentration of 16-fold 
higher than the MIC (=1 μg/ml, Table 1). The biofilm formation 
of the strain was inhibited in a similar manner by 16 μg/ml 
of vancomycin and by the corresponding NP-VANCO 
preparation: the adherent biomass decreased of about 70% and 
CFUs/well of about 3 Log units (Figure  3K). Considering the 
planktonic population, 4 and 3 Log unit reductions were 
observed in cell counting for vancomycin and NP-VANCO 
treated samples, respectively (Figure  3L).
Nanoconjugated Teicoplanin to Counteract 
Staphylococcus aureus Biofilm Formation
Since the above results on the effect of nanoconjugated GPAs 
on S. aureus biofilm formation indicated the better performance 
of NP-TEICO in comparison to NP-VANCO, further 
investigations were dedicated to studying the biofilm formation 
in the presence of nanoconjugated teicoplanin by confocal 
microscope analyses. The better producer of biofilm biomass, 
S. aureus ATCC 6538P, was selected for these experiments. 
Bacterial cells were treated with 4 μg/ml of nonconjugated or 
nanoconjugated teicoplanin and biofilm development was allowed 
on glass surfaces for 24 h at 37°C. Then, cells and biofilm 
matrix became visible thanks to the fluorophore administration 
(Figure 4A). The addition of IONPs determined the formation 
of a biofilm more homogeneous than the control one. The 
addition of teicoplanin and of NP-TEICO prevented the formation 
of a well-structured biofilm, if compared to the controls: under 
nonconjugated and nanoconjugated antibiotic treatment, only 
few fluorescent cells were observed and no matrix was visible 
(Figure  4A).
Considering that the advantage of using NP-TEICO might 
consist in directing magnetic nanoconjugated antibiotic towards 
the area of interest using an external magnetic field, we mimicked 
the hypothetical treatment of a contaminated surface attracting 
NP-TEICO on a small area (the center of a well in a 24-well 
polystyrene plate) to evaluate its effect on S. aureus 6538P 
biofilm formation (Figure  4B). Teicoplanin administered at 
the concentration of 1 μg/ml inhibited by ca. 34% the biofilm 
formation when compared to untreated S. aureus (Figures 4B,C). 
The treatment of bacteria with NP-TEICO, inhibited of ca. 
43% the biofilm formation with respect to IONPs (Figures 4B,C). 
The application of an external magnet field attracted the 
nanoparticles at the center of the well and a clear inhibition 
halo in the crystal violet staining indicated the localized 
inhibitory effect around NP-TEICO (Figure  4B).
Cytotoxicity and Macrophage 
Phagocytosis of Nanoconjugated GPAs
Cytotoxicity of nanoconjugated and nonconjugated GPAs was 
investigated using the well-established immortalized tumor cell 
line SKOV-3 (Cappellini et  al., 2015). Both teicoplanin and 
vancomycin are antibiotics without any detectable cytotoxicity 
effect, also when tested at nearly 100-fold their MICs on 
susceptible bacteria. Indeed, SKOV-3 cells responded to exposure 
to IONPs, NP-TEICO and NP-VANCO – tested at concentrations 
in the range of antibacterial MICs – in a dose-dependent 
manner (Figure  5). As reported previously (Bava et  al., 2013; 
Armenia et  al., 2018), naked IONPs themselves exerted a 
cytotoxic effect: at 5 μg/ml (Figure 5A), cell viability was reduced 
of about 20%, in comparison to untreated cells, independently 
from exposure time, whereas at nearly 50 μg/ml (Figure  5B), 
naked IONPs reduced cell viability by more than 60% (after 
24 h of exposure) to 50% (after 96 h). In the case of NP-TEICO, 
when the antibiotic was supplemented at a concentration in 
the range of antibacterial MICs towards susceptible bacteria 
(0.9 μg/ml; Figure  5A), cell viability was reduced by no more 
than 33% (after 96 h of exposure). At a concentration 10 times 
higher (9 μg/ml; Figure  5B), cell viability was decreased from 
39% (after 24 h) to 1.4% (after 96 h). For NP-VANCO, at 0.9 μg/
ml no significant decrease in cell viability was observed at 
96 h (Figure  5A), whereas at 9 μg/ml the reduction in cell 
viability was no more than 17% (after 96 h of exposure; 
Figure  5B). All together these data confirm what already 
reported by other authors, i.e., the coverage of IONPs with 
nontoxic molecules tends to reduce their intrinsic cytotoxicity 
and improve their biocompatibility in the range of antimicrobial 
effective concentrations (Xiang et  al., 2017; Armenia et  al., 
2018; Xie et  al., 2018). On the other hand, no difference was 
observed in the macrophage uptake of NP-TEICO, NP-VANCO, 
or of their naked nanocarriers, assayed using the Prussian 
Blue staining (Figure 6). The characteristic blue color developing 
from the reaction of potassium ferrocyanide with NP ferric 
ions highlighted a comparable macrophage dose-dependent 
uptake of nanoconjugated antibiotics or of their nanocarriers 
in 24 h. That macrophages engulfed IONPs, NP-TEICO, and 
NP-VANCO in a comparable mode confirmed what was already 
reported by other authors, i.e., that when macrophages are 
exposed in vitro to nanomaterials, they usually engulf them 
(Qie et  al., 2016; Verçoza et  al., 2019).
DISCUSSION
In our previous paper (Armenia et al., 2018), we demonstrated 
that NP-TEICO systems could be  prepared and used against 
Gram-positive pathogens. In that case, teicoplanin (but not 
vancomycin) was conjugated to APTES-functionalized IONPs, 
using standard EDC/NHS (N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride/N-hydroxysuccinimide) 
chemistry. In this work, we have introduced the homobifunctional 
cross-linker BS3, with the goal to improve GPA loading on 
IONPs thanks to the protruding arms of the linker and the 
reactivity of the free amino groups of the GPAs (one in 
teicoplanin and two in vancomycin). With this reaction, 
we  improved the conjugation efficiency. Indeed, in this work, 
we  have loaded more than 150 μg of teicoplanin on average 
per mg of IONPs instead of the nearly 100 μg (Armenia et  al., 
2018). Additionally, in this paper, we applied the new conjugation 
reaction to vancomycin, which was linked to IONPs at a 
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concentration higher than 200 μg for mg of IONPs. It is worth 
noting that in our previous trials using EDC/NHS chemistry 
with vancomycin, we  never obtained stable NP-VANCO 
preparations (unpublished results), although in the literature 
it is reported that the carboxylic group of vancomycin could 
be  used, similarly to that of teicoplanin, for the binding to 
NPs (Kell et  al., 2008; Zhu et  al., 2015; Chen et  al., 2019). It 
is anyhow true that the comparison of the loading capacity 
of the different preparations is quite challenging due to the 
great variability in size, geometry, crystalline structure, and 
capping polymers used with IONPs (Kell et  al., 2008; Wu 
et  al., 2015; Wang et  al., 2019). Importantly, our 
superparamagnetic NP-TEICO and NP-VANCO, with an average 
diameter of approximately 10 nm, were chemically stable (slightly 
more NP-TEICO than NP-VANCO) and could be  stored at 
different temperatures.
Antimicrobial Activity of GPA-NP Systems
While nanoconjugation partially reduced NP-VANCO 
antimicrobial activity in comparison to nonconjugated 
vancomycin, the prepared NP-TEICO maintained the typical 
GPA antimicrobial spectrum of activity towards Gram-positive 
bacteria, including clinical isolates and resistant strains (Van 
A B
C
FIGURE 4 | Effect of nonconjugated and nanoconjugated teicoplanin on S. aureus ATCC 6538P biofilm on different surfaces. Panel A: CLSM images of S. aureus 
ATCC 6538P biofilm on glass surface, grown for 24 h without any addition (CTRL) or in the presence of nonconjugated (TEICO) or nanoconjugated (NP-TEICO) 
teicoplanin at 4 μg/ml, or with an equivalent amount of IONPs. Panel B: S. aureus ATCC 6538P biofilm formation in 24-well polystyrene plate, exposed to a magnet 
(5 × 5 × 5 mm) localized under each well. The bacteria were grown 24 h on the plastic surface in different conditions: without any treatment (CTRL), incubated with 
nonconjugated teicoplanin (TEICO) or with nanoconjugated teicoplanin (NP-TEICO) added in both cases at 1 μg/ml, or with an equivalent amount of IONPs. Panel C: 
Adherent biomass formation in 24-well polystyrene plate after 24 h of bacterial growth at 37°C, quantified spectrophotometrically at 590 nm after crystal violet 
staining. Statistical analyses were performed by one-way ANOVA (**p < 0.01).
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Bambeke, 2006; Binda et  al., 2014; Yushchuk et  al., 2020b). 
NP-TEICO was more active than NP-VANCO on VanB-resistant 
enterococci, NP-VANCO was more active than NP-TEICO on 
S. haemolyticus, whereas both preparations were not active 
against VanA enterococci and the Gram-negative representative 
E. coli. Although many authors have previously reported that 
IONPs, as well as other types of metal oxide NPs, possess an 
intrinsic antimicrobial activity (Gabrielyan et  al., 2019; Das 
et al., 2020; Shkodenko et al., 2020), in the different experiments 
hereby conducted (i.e., agar diffusion assay, BacLight fluorescence 
assay, bacterial growth kinetics, CFU measurement) a significant 
bacteriostatic and bactericidal activity was conferred to IONPs 
only following their conjugation with teicoplanin and vancomycin. 
As previously reported (Ebrahiminezhad et  al., 2014; Arakha 
et  al., 2015; Dinali et  al., 2017; Armenia et  al., 2018), naked 
IONPs can interact mainly via electrostatic interactions with 
bacterial cell envelopes, arresting transiently cell growth and, 
in sporadic cases, causing cell death, but this phenomenon 
greatly differs in magnitude from the potent and selective 
antimicrobial action of ‘last-resort’ antibiotics such as GPAs 
towards Gram-positive bacterial strains. In a recent review, 
Shkodenko et  al. (2020) reported that in general naked IONPs 
have to be  used at mg/l concentrations to show some 
antibacterial activity.
Antibiofilm Activity of GPA-NP Systems
Although some published reports indicated that IONPs exert 
an inhibitory activity on biofilms formed by food associated 
bacteria (Al-Shabib et  al., 2018) or by S. aureus, E. coli, and 
Pseudomonas aeruginosa growing on different polymeric surfaces 
(Thukkaram et  al., 2014), our results on S. aureus biofilm 
clearly demonstrated that at the concentrations at which 
nonconjugated and nanoconjugated GPAs are active, IONPs 
per se did not exert any appreciable inhibitory effect. Similarly 
to gold and silver NPs, IONPs might exert an inhibitory effect 
on biofilm-embedded cells by causing a mechanical disruption 
of the biofilm matrix (Li et  al., 2019) and by intercepting 
those non-specific interactions (electrostatic, hydrophobic, 
hydrogen-bonding, ionic, and van der Waal interactions) that 
are responsible for the adhesion of biofilm-forming bacteria 
to surfaces (Joshi et  al., 2020). These effects, however, become 
evident at relatively high concentrations of IONPs (Joshi et  al., 
2020; Shkodenko et  al., 2020). As reported by Al-Shabib et  al. 
(2018), IONPs can inhibit production of alginate, which is a 
key component of the extracellular polymeric matrix in 
P. aeruginosa biofilm, or of other exopolysaccharides that 
maintain the biofilm architecture and act as protective barrier. 
Biofilm structure and composition are complex and dramatically 
differ from species to species and even among strains belonging 
to same species, as in the case of S. aureus (Rose and Poppens, 
2009; Artini et  al., 2012). Thus, it is not surprising that the 
responses to NP-based formulations are variable, since they 
might depend on particular combinations of different factors 
such as biofilm maturity and surface composition on the one 
side, and chemistry, nanoparticle size, surface charge, surface 
chemistry, and NP concentration on the other side (Arias et al., 
2018; Joshi et  al., 2020).
Since the early 1960s, vancomycin has been the first-choice 
drug for treating patients infected by invasive MRSA, but its 
use is currently limited by slow antibacterial speed, low tissue 
penetration, and increasing drug resistance. Moreover, penetration 
of vancomycin into viable S. aureus biofilms analyzed by confocal 
scanning laser microscopy was found extremely low 
A B
FIGURE 5 | Cell viability of SKOV-3 after exposure up to 96 h to IONPs (green bars), teicoplanin (violet), NP-TEICO (orange), vancomycin (turquoise), or NP-VANCO 
(blue). Cell viability was expressed as a percentage of viable cells compared to the untreated sample, set as 100%. The amount of nonconjugated or 
nanoconjugated GPA to be added was as follows: 0.9 μg/ml (panel A) and 9 μg/ml (panel B). In the case of nanoGPAs and IONPs, the amounts to be added were 
defined considering the antibiotic loaded on IONPs under the conditions described in Material and Methods. The values are expressed as mean ± standard deviation 
of three independent experiments. One-way ANOVA analysis, *p < 0.05; **p < 0.01; ***p < 0.0001.
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(Jefferson et  al., 2005). Although teicoplanin offers several 
advantages over vancomycin, such as a longer half-life, better 
stability in vivo, lower nephrotoxicity and ototoxicity, and 
activity on VanB-phenotype vancomycin-resistant pathogens, 
its action on biofilm formation has not been adequately 
investigated, yet. Our results showed that teicoplanin and, albeit 
at a less extent, vancomycin could reduce biofilm formation 
by the three different strains of S. aureus used in this study, 
FIGURE 6 | Uptake by THP-1 cells after 24 h of incubation with 5 μg/ml of IONPs (panel B), 50 μg/ml of IONPs (panel C), 5 μg/ml of NP-TEICO (panel D), 50 μg/ml 
of NP-TEICO (panel E), 5 μg/ml of NP-VANCO (panel F), 50 μg/ml of NP-VANCO (panel G) and control untreated cells (panel A). Prussian Blue staining of NP ferric 
ions was observed at the optical microscope; bars are 20 μm.
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two MSSA and one MRSA. The relative impact of the two 
GPAs differed on the three strains, the MRSA being the most 
resistant as reported by other authors (Fulaz et  al., 2020; Gao 
et  al., 2020). The nanoconjugated GPAs maintained the same 
activities as the two nonconjugated counterparts, being 
NP-TEICO more active than NP-VANCO. Teicoplanin differs 
from vancomycin for its lipid chain that confers it a superior 
antimicrobial potency. The lipid chain better anchors teicoplanin 
to the membrane/cell wall interface where the antibiotic binds 
to the d-alanyl-d-alanine terminus of the peptidoglycan 
precursors, arresting cell wall biosynthesis (Treviño et al., 2014; 
Yushchuk et  al., 2020a). It would be  interesting to investigate 
further if the more hydrophobic nature of teicoplanin in 
comparison to vancomycin might explain its improved activity 
on biofilm formation.
Potential Advantage of GPA-NP Systems
Advantages of using NP-TEICO instead of the soluble teicoplanin 
counterpart are due to the magnetic properties of the carrying 
IONPs that can be  directed by an external magnetic field to 
a specific site, as a biofilm-colonized surface, increasing the 
local drug concentration. We  showed that NP-TEICO could 
be  attracted by an external magnet and that it drastically 
reduced biofilm formation around its concentration zone. The 
concept can be extended to targeting a deep soft tissue infection, 
or reaching infected tissues or organs, reducing the need of 
using elevated doses to treat resistant bacteria and concomitantly 
limiting toxic side effects. Although further investigations are 
needed to develop adequate experimental systems and animal 
models to study the antimicrobial and anti-biofilm potential 
of NP-TEICO highlighted in this paper, we  think that these 
lines of evidence pave the way for a promising use of NP-TEICO 
and more in general of IONPs carrying other novel GPAs. 
This approach can also be extended in future for the controlled 
and targeted use of other last-resort potent molecules such as 
daptomycin and polymyxins. The targeting therapy concept 
originates from and is widely used in cancer therapy (Naskar 
and Kim, 2019; Ajinkya et  al., 2020) but the times are mature, 
due to a dramatic increase in AMR, to shift it to the anti-
infective therapeutic area.
Nanotoxicity of GPA-NP Systems
A still unsolved issue of using IONP-carried antibiotics remains 
assessing their intrinsic level of cytotoxicity, which could 
eventually limit their further in vivo utilization (Wu et  al., 
2015; Arias et  al., 2018). Although IONPs are considered the 
most biocompatible among metal oxide NPs and many clinical 
applications based on their use in vivo have been already 
proposed (i.e., magnetic resonance imaging, thermal ablation 
therapy, treatment of iron-deficient anemia; Arias et  al., 2018; 
Ajinkya et  al., 2020; Wang et  al., 2020), the knowledge on 
their interaction with animal cells and models is still very 
limited (Naskar and Kim, 2019; Das et  al., 2020). Herein, 
we  report that the cytotoxic effect of IONPs to mammalian 
cell lines in vitro, when used in the range of the antibacterial 
MICs of GPAs, is relatively low and it seems to be  mitigated 
by the coverage with non-toxic molecules such as GPAs 
themselves. Nevertheless, a complete assessment of nanomaterial 
toxicity requires considering their administration routes, 
distribution and stability inside the different body districts, 
factors that can be  investigated only through in vivo studies.
Another correlated aspect that needs to be further investigated 
in vivo is how rapidly and efficiently host phagocytes, if recruited, 
might engulf nanoantibiotics. We  hereby reported that in vitro 
cultures of macrophages engulfed both bare and antibiotic-
conjugated IONPs. This is not surprising since several studies 
have shown that macrophages internalize NPs (Verçoza et  al., 
2019), although, in principle, their surface modifications might 
allow evasion of phagocytic clearance (Qie et  al., 2016). In 
any case, little is known about the in vivo recruitment of 
macrophages by nanomaterials and, a fortiori, by nanoantibiotics, 
depending again on their administration routes, body district 
distribution and physicochemical properties of their surface. 
Cappellini et  al. (2015) evaluated the biodistribution of a 
nanoenzyme system in vivo 24-h post-treatment, and reported 
that intravenously injected IONPs were found mainly in the 
cytoplasm of Kupffer cells and spleen histocytes, and no 
macrophage recruitment was detectable in heart, testis, and 
brain. Bonfanti et  al. (2020) observed that Xenopus laevis 
embryos accumulated IONPs in their gut (IONPs were found 
dispersed within the enterocytes of a well-preserved intestinal 
epithelium), without causing any acute toxicity nor teratogenicity.
Future Perspectives
Infection animal models are urgently needed for better 
evaluating the potential of nanoconjugated antibiotics for 
topic, oral, or systemic use, including their stability toward 
the proteolytic activity and to the different pHs occurring 
at sites of infection. To the best of our knowledge, there is 
only one study on an IONP-conjugated GPA tested in an 
infection animal model. This is the case of the recent work 
of Chen et  al. (2019), who reported the effect of IONPs 
carrying vancomycin on C. difficile in mice infection model, 
demonstrating that nanoconjugated vancomycin exerted a 
therapeutic effect higher than free vancomycin, reducing 
intestinal inflammation, facilitating mucosal viability, and 
limiting the antibiotic side effects on intestinal microbiota. 
Our next goal is to test NP-TEICO and NP-VANCO in the 
invertebrate infection model that we  have recently developed 
for comparing GPA efficacy in curing in vivo infections 
(Montali et  al., 2020). We  employed easy-to-handle larvae of 
the silkworm Bombyx mori infected by S. aureus. Due to its 
great advantages (i.e., safe handling, low rearing costs, low 
antibiotic amount needed, no restrictions imposed by ethical 
and regulatory issues), this silkworm infection model could 
help in rapidly solving pending issues about in vivo efficacy 
and toxicity of nanoconjugated antibiotics. Only few papers 
reported on testing nanomaterials in insect models (Thomaz 
et  al., 2020; Moya-Andérico et  al., 2021). Indeed, they might 
be  useful to gain a better understanding of the physiological 
responses of living organisms to nanomaterials and to speed 
up their development towards clinical applications.
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CONCLUDING REMARKS
In conclusion, in this paper we  described novel 
nanoformulations of teicoplanin and vancomycin covalently 
conjugated to IONPs. These nanoformulations were chemically 
stable and especially NP-TEICO conserved the typical spectrum 
of antimicrobial activity of the nonconjugated glycopeptide 
antibiotic. NP-TEICO and, although to a lesser extent, 
NP-VANCO were effective in reducing S. aureus biofilm 
formation. In particular, when concentrated by the action of 
an external magnetic field, NP-TEICO exerted a localized 
inhibitory effect on biofilm formation even at a very low 
antibiotic concentration. Finally, we proved that the conjugation 
of GPAs to IONPs reduced their intrinsic cytotoxicity toward 
a human cell line, thus paving the way for their study in 
animal models.
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